Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment

LAUR Repository

Show simple item record

dc.contributor.author Matli, Kamal
dc.contributor.author Farah, Raymond
dc.contributor.author Maalouf, Mario
dc.contributor.author Chamoun, Nibal
dc.contributor.author Costanian, Christy
dc.contributor.author Ghanem, Georges
dc.date.accessioned 2022-03-11T12:32:51Z
dc.date.available 2022-03-11T12:32:51Z
dc.date.copyright 2021 en_US
dc.date.issued 2022-03-10
dc.identifier.issn 2053-3624 en_US
dc.identifier.uri http://hdl.handle.net/10725/13386
dc.description.abstract Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic and thromboembolic events. Therefore, understanding the effect of antiplatelet and anticoagulation therapy in the context of COVID-19 treatment is important. The aim of this rapid review was to highlight the role of thrombosis in COVID-19 and to provide new insights on the use of antithrombotic therapy in its management. A rapid systematic review was performed using preferred reporting items for systematic reviews. Papers published in English on antithrombotic agent use and COVID-19 complications were eligible. Results showed that the use of anticoagulants increased survival and reduced thromboembolic events in patients. However, despite the use of anticoagulants, patients still suffered thrombotic events likely due to heparin resistance. Data on antiplatelet use in combination with anticoagulants in the setting of COVID-19 are quite scarce. Current side effects of anticoagulation therapy emphasise the need to update treatment guidelines. In this rapid review, we address a possible modulatory role of antiplatelet and anticoagulant combination against COVID-19 pathogenesis. This combination may be an effective form of adjuvant therapy against COVID-19 infection. However, further studies are needed to elucidate potential risks and benefits associated with this combination. en_US
dc.language.iso en en_US
dc.title Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle a rapid review en_US
dc.author.school SOP en_US
dc.author.school SOM
dc.author.idnumber 200201071 en_US
dc.author.idnumber 201000163 en_US
dc.author.department Pharmacy Practice en_US
dc.relation.journal Open Heart en_US
dc.journal.volume 8 en_US
dc.journal.issue 1 en_US
dc.article.pages e001628 en_US
dc.identifier.doi http://dx.doi.org/10.1136/openhrt-2021-001628 en_US
dc.identifier.ctation Matli, K., Farah, R., Maalouf, M., Chamoun, N., Costanian, C., & Ghanem, G. (2021). Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. Open heart, 8(1), e001628. en_US
dc.author.email nibal.chamoun@lau.edu.lb en_US
dc.author.email george.ghanem@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://openheart.bmj.com/content/8/1/e001628.abstract en_US
dc.note This article has a correction inserted at the end of the article plus supplemntal material provided by the auhors en_US
dc.orcid.id https://orcid.org/0000-0002-0987-296X en_US
dc.orcid.id https://orcid.org/ 0000-0002-0850-0689 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account